Berlin-based Biopharma AI provider, Reliant AI, announced its stealth debut with €10.1 million in a seed funding round to advance data analytics solutions.
Tola Capital and Inovia Capital spearheaded the additional round, with angel investor Mike Volpi contributing as well.
With the fresh capital, the company plans to acquire engineering expertise to increase its technological investment and footprints in North America and Europe, with a primary focus on the biopharmaceutical industry.
Leading experts in NLP and reinforcement learning, Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel developed Reliant AI. Additionally, they are enthusiastic about how generative AI might resolve information-related problems to lessen monotonous mental work and expedite business decision-making.
Karl Moritz Hermann, CEO and co-founder of Reliant AI, said:
“A very important but often disregarded component of the life sciences’ advancement toward a better society is information and data. Today’s data-intensive companies require a staggering amount of mundane labor, so many highly qualified experts are more interested in wrangling data than in finding complicated solutions. We built an AI system that comprehends the life sciences to dramatically grow its capacity to perform research at scale.”
Related Content: Clinical Trial Revolutionized by Rivia’s Biotech AI Analytics
The AI workbench, Reliant Tabular, the debut product of Reliant AI, is garnering a lot of interest from important biopharma business categories. Moreover, Reliant AI is software that assists life science analysts in finding scientific evidence to support their judgments. Specifically, it does this by providing automatic systematic reviews, asset scans, thorough analyses, and a customizable data platform that allows you to query anything.
Reliant Tabular’s features include proprietary ML models that are trained to be biopharma topic experts. Additionally, it employs a thorough fact-finding approach that maximizes recall to ensure nothing is missed. Furthermore, it offers an intuitive user interface that facilitates the quick and simple reconciliation of generated results with real-world evidence. Moreover, responses are provided in a format suitable for reporting, allowing teams to work together on analyses.
Investors Thought:
Aaron Fleishman, partner at Tola Capital, stated:
“There is a huge and unmet information requirement in the biopharma business. Reliant AI creates software that can do a day’s worth of data wrangling in 30 seconds by combining state-of-the-art research with domain expertise. Marc, Karl Moritz, and their technical team bring decades of AI expertise from the world’s best research groups, like DeepMind, Google Brain, and Meta, giving Reliant the ability to move the needle on the application of generative AI to hard data problems.”
Steve Woods, a partner at Inovia Capital, said:
“We see a significant market opportunity in the pharmaceutical sector as companies strive to build and partner with new entrants to develop innovative solutions like those offered by Reliant AI. Moreover, this noteworthy demand in a sizable and expanding market highlights AI’s potential to drive significant advancements in the biopharmaceutical sector.”
